HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jedd D Wolchok Selected Research

tyrosinase-related protein-1

11/2016An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.
12/2008Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
5/2006Optimization of a self antigen for presentation of multiple epitopes in cancer immunity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jedd D Wolchok Research Topics

Disease

241Neoplasms (Cancer)
11/2022 - 01/2002
194Melanoma (Melanoma, Malignant)
10/2022 - 01/2002
15Disease Progression
01/2020 - 01/2008
13Neoplasm Metastasis (Metastasis)
01/2021 - 12/2008
11Experimental Melanoma
11/2021 - 05/2003
10Brain Neoplasms (Brain Tumor)
01/2018 - 09/2003
9Body Weight (Weight, Body)
10/2019 - 08/2010
8Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/2019 - 08/2015
7Inflammation (Inflammations)
01/2021 - 03/2014
7Prostatic Neoplasms (Prostate Cancer)
04/2019 - 10/2003
7Colitis
11/2018 - 05/2012
6Lung Neoplasms (Lung Cancer)
01/2022 - 04/2015
6Testicular Neoplasms (Testicular Cancer)
01/2021 - 02/2005
5Carcinoma (Carcinomatosis)
11/2022 - 05/2010
5Uveal melanoma
05/2022 - 04/2011
5COVID-19
01/2021 - 01/2020
5Breast Neoplasms (Breast Cancer)
12/2016 - 04/2004
5Vitiligo
07/2014 - 07/2002
4Communicable Diseases (Infectious Diseases)
11/2017 - 01/2002
4Exanthema (Rash)
12/2016 - 05/2012
3Infections
05/2017 - 12/2012
3Hypersensitivity (Allergy)
01/2017 - 07/2010
3Fatigue
08/2015 - 05/2012
3Sarcoma (Soft Tissue Sarcoma)
03/2005 - 11/2003
2Neoplasm Micrometastasis
01/2021 - 11/2003
2Bites and Stings (Sting)
01/2021 - 05/2017
2Renal Cell Carcinoma (Grawitz Tumor)
10/2019 - 01/2018
2Microsatellite Instability
04/2019 - 01/2017

Drug/Important Bio-Agent (IBA)

99IpilimumabIBA
10/2022 - 01/2008
48Immune Checkpoint InhibitorsIBA
11/2022 - 07/2013
37NivolumabIBA
10/2022 - 07/2013
37AntibodiesIBA
02/2021 - 07/2002
35DNA (Deoxyribonucleic Acid)IBA
01/2022 - 01/2002
33AntigensIBA
01/2021 - 01/2002
29Monoclonal AntibodiesIBA
10/2019 - 11/2003
23pembrolizumabIBA
01/2022 - 07/2013
22Biomarkers (Surrogate Marker)IBA
01/2021 - 01/2011
19Proteins (Proteins, Gene)FDA Link
10/2021 - 04/2004
19VaccinesIBA
01/2021 - 01/2002
19DNA VaccinesIBA
08/2017 - 01/2002
15CTLA-4 AntigenIBA
01/2018 - 12/2008
14Monophenol Monooxygenase (Tyrosinase)IBA
08/2017 - 04/2003
14Neoplasm Antigens (Tumor Antigens)IBA
05/2017 - 01/2003
14AutoantigensIBA
05/2014 - 10/2002
13Peptides (Polypeptides)IBA
01/2022 - 05/2003
10B7-H1 AntigenIBA
10/2021 - 11/2016
10Programmed Cell Death 1 ReceptorIBA
01/2021 - 07/2013
10Differentiation AntigensIBA
09/2010 - 05/2003
9Pharmaceutical PreparationsIBA
01/2021 - 12/2011
8GlucocorticoidsIBA
10/2021 - 04/2009
8InterferonsIBA
01/2021 - 08/2015
7Blocking AntibodiesIBA
01/2021 - 01/2011
7EpitopesIBA
11/2017 - 05/2003
7Temozolomide (Temodar)FDA LinkGeneric
06/2014 - 09/2003
6Dacarbazine (DIC)FDA LinkGeneric
04/2015 - 02/2004
5Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
10/2021 - 04/2009
5EnzymesIBA
11/2020 - 08/2011
5Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2014 - 02/2009
4Cancer VaccinesIBA
01/2022 - 12/2008
4Immunoglobulin G (IgG)IBA
02/2021 - 09/2006
4Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA
11/2020 - 08/2011
4Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2019 - 04/2013
4RNA (Ribonucleic Acid)IBA
01/2017 - 05/2003
4Biological ProductsIBA
01/2017 - 01/2002
4CytokinesIBA
12/2016 - 09/2006
4LigandsIBA
07/2015 - 05/2006
4Imatinib Mesylate (Gleevec)FDA Link
05/2015 - 05/2011
4HLA-A*02:01 antigenIBA
10/2010 - 11/2007
4Thalidomide (Thalomid)FDA Link
03/2007 - 09/2003
3Alkylating AgentsIBA
10/2021 - 05/2009
3LipidsIBA
01/2021 - 11/2015
3Transcription Factors (Transcription Factor)IBA
01/2018 - 11/2013
3Interferon-gamma (Interferon, gamma)IBA
01/2017 - 02/2009
3tyrosinase-related protein-1IBA
11/2016 - 05/2006
3Glycoproteins (Glycoprotein)IBA
11/2016 - 08/2010
3Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
04/2016 - 06/2011
3Complement System Proteins (Complement)IBA
01/2016 - 05/2003
3Interferon Type IIBA
08/2015 - 01/2014
3Interleukin-2 (IL2)IBA
01/2015 - 04/2011
3Therapeutic UsesIBA
05/2014 - 09/2010
3HLA Antigens (Human Leukocyte Antigens)IBA
01/2013 - 11/2007
3Oncogene Proteins (Oncogene Protein)IBA
06/2012 - 07/2010
3Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
12/2008 - 01/2002
2Arginine (L-Arginine)FDA Link
05/2022 - 04/2013
2PhosphatidylserinesIBA
12/2021 - 12/2021
2Protein Isoforms (Isoforms)IBA
11/2021 - 06/2012
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2021 - 05/2009
2cyclic guanosine monophosphate-adenosine monophosphateIBA
01/2021 - 05/2017
2Phosphotransferases (Kinase)IBA
01/2021 - 11/2016
2Cell-Free Nucleic AcidsIBA
01/2020 - 12/2017
2Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
04/2019 - 01/2019

Therapy/Procedure

124Therapeutics
11/2022 - 01/2002
98Immunotherapy
01/2022 - 01/2002
12Drug Therapy (Chemotherapy)
04/2019 - 06/2005
10Radiotherapy
12/2021 - 06/2010
9Aftercare (After-Treatment)
01/2020 - 11/2003
5Immunomodulation
01/2017 - 03/2013
4Ligation
11/2013 - 05/2006
3Time-to-Treatment
01/2020 - 10/2015
2Artificial Respiration (Mechanical Ventilation)
05/2020 - 01/2020